Core Viewpoint - Company Jinshi Yao (300434.SZ) has received approval from the National Medical Products Administration for its subsidiary Zhejiang Yake Pharmaceutical Co., Ltd. to market Glucosamine Sulfate Capsules, which are classified as non-prescription analgesics for osteoarthritis treatment [1] Group 1: Product Approval - The approval includes the issuance of a Drug Registration Certificate for Glucosamine Sulfate Capsules, which is considered equivalent to passing the consistency evaluation [1] - Glucosamine is a natural amino monosaccharide that serves as a precursor for the synthesis of proteoglycans, enhancing the repair capacity of chondrocytes [1] Group 2: Product Functionality - The capsules are indicated for primary and secondary osteoarthritis, helping to alleviate joint pain and improve joint function [1] - Glucosamine can inhibit enzymes that damage cartilage, such as collagenase and phospholipase A2, and prevent the production of superoxide free radicals that harm cells [1] - The product promotes the repair and reconstruction of cartilage matrix, potentially delaying the pathological process of osteoarthritis and improving patient outcomes [1]

Core Viewpoint - The company Jinshi Yiyao (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has received the drug registration certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [1] Group 1: Product Information - Glucosamine Sulfate Capsules are classified as non-prescription analgesic drugs, indicated for primary and secondary osteoarthritis [1] - Glucosamine is a natural amino monosaccharide that serves as a precursor for the synthesis of proteoglycans, stimulating chondrocytes to produce proteoglycans with normal polymer structures [1] - The product enhances the repair capacity of chondrocytes, inhibits damaging enzymes such as collagenase and phospholipase A2, and prevents the production of superoxide free radicals in damaged cells, promoting the repair and reconstruction of cartilage matrix [1] Group 2: Therapeutic Benefits - The capsules can delay the pathological process of osteoarthritis pain and the progression of the disease, improve joint mobility, and alleviate pain [1]

Group 1 - The core point of the article is that Jinshi Yiyao has received approval for its glucosamine sulfate capsule from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [1] - Jinshi Yiyao's revenue composition for the first half of 2025 is as follows: 82.76% from the pharmaceutical manufacturing industry, 14.09% from the machinery manufacturing industry, and 3.16% from real estate leasing and management [1] - As of the report date, Jinshi Yiyao has a market capitalization of 4.8 billion yuan [1]

证券代码：300434 证券简称：金石亚药 公告编号：2025-044 四川金石亚洲医药股份有限公司 关于全资子公司获得硫酸氨基葡萄糖胶囊药品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，四川金石亚洲医药股份有限公司（以下简称"公司"）全资二级子公 司浙江亚克药业有限公司（以下简称"亚克药业"）收到国家药品监督管理局核 准签发的硫酸氨基葡萄糖胶囊《药品注册证书》，且视同通过一致性评价。现将 相关情况公告如下： 药品英文名称：Glucosamine Sulfate Capsules 剂型：胶囊剂 规格：0.25g（按硫酸氨基葡萄糖计）或 0.314g(按硫酸氨基葡萄糖氯化钠 计) 注册分类：化学药品 4 类 上市许可持有人：浙江亚克药业有限公司 上市许可持有人地址：浙江省杭州市滨江区浦沿街道东冠路 611 号 1 幢 2 楼 201-209 室 一、药品基本情况 药品名称：硫酸氨基葡萄糖胶囊 应当符合药品生产质量管理规范要求方可生产销售。 生产企业：浙江亚峰药厂有限公司 生产企业地址：浙江省金华市金衢路 68 号 证书编号：2025S03 ...

Core Viewpoint - The company, Kingstone Pharmaceuticals, announced that its wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which is considered equivalent to passing the consistency evaluation [1] Group 1 - The approved product, Glucosamine Sulfate Capsules, is a non-prescription analgesic medication [1] - The indications for Glucosamine Sulfate Capsules include primary and secondary osteoarthritis [1]

Core Viewpoint - The company has received approval for its glucosamine sulfate capsules, which are indicated for osteoarthritis, marking a significant milestone in its product development and market entry strategy [1] Group 1: Company Developments - The company's wholly-owned subsidiary, Zhejiang Yake Pharmaceutical Co., Ltd., has been granted a drug registration certificate for glucosamine sulfate capsules by the National Medical Products Administration (NMPA) [1] - The approval is considered equivalent to passing the consistency evaluation for generic drugs, enhancing the company's competitive position in the market [1] Group 2: Product Information - Glucosamine sulfate capsules are classified as non-prescription analgesic medications, specifically indicated for primary and secondary osteoarthritis [1] - The application for this product was submitted to the NMPA in May 2024 and has since been accepted [1] Group 3: Market Context - As of the announcement date, over twenty manufacturers, including the company, have either passed or are deemed to have passed the consistency evaluation for glucosamine sulfate capsules [1]

Core Viewpoint - The company, Jinsiyaya Pharmaceutical, announced that its subsidiary, Zhejiang Deer Pharmaceutical, has received approval from the National Medical Products Administration for its Diclofenac Sodium Sustained-release Tablets (0.1g) after passing the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - Jinsiyaya Pharmaceutical's subsidiary, Zhejiang Deer Pharmaceutical, is a wholly-owned secondary subsidiary [1] - The approval notification number for the drug is 2025B05105 [1] - The drug is a sustained-release formulation of Diclofenac Sodium [1]

Group 1 - Jinguang Electric won a bid for a State Grid procurement project with a total amount of 21.7976 million yuan, accounting for approximately 2.93% of the company's expected revenue for 2024 [1] - Shen Gong Co. plans to reduce its shareholding by up to 2%, equating to 340.61 million shares [2] - Guomai Culture received a government subsidy of 3.78 million yuan, representing 24.90% of its audited net profit for 2024 [2] Group 2 - Guomai Culture focuses on the development and provision of digital content operation platforms [3] - Shentong Technology's two directors plan to collectively reduce their shareholding by no more than 0.0473% [4] - Ruihua Tai intends to reduce its shareholding by up to 1%, amounting to 1.8 million shares [5] Group 3 - Guoji Automobile's wholly-owned subsidiary won a total contract project worth 809 million yuan [7] - Changcheng Technology's stock is expected to remain suspended due to potential changes in control [9] - Huabei Pharmaceutical's subsidiary received approval for a chemical raw material drug listing application [11] Group 4 - Fuyao Glass has changed its legal representative to Cao Hui [13] - Huaxi Biological plans to reduce its shareholding by up to 2%, totaling 9.6336 million shares [14] - Hopu Co. signed a procurement contract for a storage system worth 500 million yuan [15] Group 5 - ST Songfa's subsidiary plans to invest 458 million yuan in a mooring dock project [18] - Zhonghong Medical's subsidiary is expected to be selected for several centralized procurement projects [19] - Huakai Yibai's vice chairman plans to increase his shareholding by no less than 30 million yuan [20] Group 6 - Haichuang Pharmaceutical completed the first participant enrollment for a clinical trial of a drug for metabolic-associated fatty liver disease [21] - Dongfang Biological's subsidiary obtained medical device product registration certificates for multiple products [22] - Lepu Medical's rechargeable implantable deep brain stimulation system received NMPA registration approval [23] Group 7 - Changyuan Power's power generation in October decreased by 32.25% year-on-year [24] - Jinshi Yaya's diclofenac sodium sustained-release tablets passed the consistency evaluation for generic drugs [26] - Yutong Bus sold 3,040 buses in October, a decrease of 5.62% year-on-year [27] Group 8 - Far East Co. signed contracts worth 1.062 billion yuan in October [28] - Tianya Pharmaceutical's subsidiary passed the consistency evaluation for a drug [29] - Yuheng Pharmaceutical plans to resolve a debt dispute through a share transfer agreement [30] Group 9 - Hailanxin's subsidiary won a bid for a marine observation network project worth 1.097 billion yuan [31] - Huasheng Lithium plans to reduce its shareholding by up to 0.37% [33] - Maike Biological obtained product registration certificates for five new in vitro diagnostic products [34] Group 10 - Huayuan New Materials signed a strategic cooperation agreement with Taiblue New Energy [37] - Greebo's actual controller and some directors plan to collectively increase their shareholding by no less than 11.5 million yuan [39] - Yian Technology received a government subsidy of 1.1643 million yuan [41] Group 11 - Kangtai Biological's quadrivalent influenza virus vaccine has commenced Phase I clinical trials [43] - Spring Airlines received a commitment letter for a stock repurchase loan of up to 450 million yuan [45] - Foton Motor sold 8,006 new energy vehicles in October, a year-on-year increase of 98.83% [46] Group 12 - Greebo plans to transfer 100% equity of its subsidiary for 280 million yuan [48] - Siwei Liekong's director is under investigation [49] - Dingyang Technology launched a new generation of multi-channel microwave signal generator products [50] Group 13 - Jiangling Motors reported a year-on-year increase of 8.06% in vehicle sales for October [51] - Shengyi Technology plans to reduce its shareholding by up to 1.03% [52] - Dongshan Precision completed the acquisition of 100% equity of France's GMD Group for approximately 814 million yuan [53] Group 14 - Tianyang Technology plans to acquire 7.5% of Baoland's shares for 155 million yuan [54] - Alter plans to establish a joint venture company with a total investment of 672 million yuan [54] - Changchun High-tech's clinical trial application for a drug was approved [55] Group 15 - Beibu Gulf Port's cargo throughput in October increased by 22.73% year-on-year [56] - ST Zhangjiajie was ruled by the court to undergo reorganization [57] - Teda Co.'s subsidiary was selected as a supplier for an energy project in Indonesia [58]

证券代码：300434 证券简称：金石亚药 公告编号：2025-043 注册分类：化学药品 四川金石亚洲医药股份有限公司 关于全资子公司药品通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四川金石亚洲医药股份有限公司（以下简称"公司"）全资二级子公司浙江 迪耳药业有限公司（以下简称"迪耳药业"）于近日收到国家药品监督管理局核 准签发的《药品补充申请批准通知书》（通知书编号：2025B05105），迪耳药业 双氯芬酸钠缓释片（0.1g 规格）通过仿制药质量和疗效一致性评价，现将相关 情况公告如下： 一、药品基本情况 药品名称：双氯芬酸钠缓释片 剂型：片剂 规格：0.1g 特此公告。 原药品批准文号：国药准字 H20083921 药品注册标准编号：YBH28882025 上市许可持有人：浙江迪耳药业有限公司 上市许可持有人地址：浙江省金华市金衢路 128 号 审批结论：根据《中华人民共和国药品管理法》《国务院关于改革药品医疗 器械审评审批制度的意见》（国发〔2015〕44 号）和《关于仿制药质量和疗效 一致性评价工作有关事项的公告》（2 ...

Core Viewpoint - Kingstone Pharmaceuticals (300434.SZ) announced that its wholly-owned subsidiary, Zhejiang Deer Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its Diclofenac Sodium Sustained-release Tablets (0.1g) after passing the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved Diclofenac Sodium Sustained-release Tablets are indicated for the relief of various chronic arthritis conditions, including rheumatoid arthritis, osteoarthritis, spondyloarthritis, gouty arthritis, and rheumatic arthritis during acute episodes or persistent joint pain [1] - The product is also indicated for various soft tissue rheumatic pains such as shoulder pain, tenosynovitis, bursitis, myalgia, and pain from sports injuries [1] - Additionally, it is indicated for acute mild to moderate pain, including pain following surgery, trauma, or strain, as well as primary dysmenorrhea, toothache, and headache [1]